Skip to content
  • Careers
  • Blog
  • Contact Us
  • English
    • French
    • German
Nexelis, a Q² Solutions Company
  • What’s Next
  • Our Services
    • Early Development Assays
    • Preclinical
    • Protein Sciences
    • Bioanalytical Services
      • Menu
    • Biomarkers
      • Menu
    • Translational Sciences
    • Assay Development and Technology Transfer
    • High-Throughput Testing
  • Our Expertise
    • Infectious Diseases
      • Vaccine
      • COVID-19
    • Immunotherapy
      • Immuno-oncology
    • Metabolic Diseases
  • About Us
    • About Us
    • Our Sites
      • Laval
      • Seattle
      • Gosselies
      • Indianapolis
      • Marburg
      • Porton Down
    • Our Scientists
  • News & Events
    • News
    • Events
  • Resources

Publication

Publication

COVID-19: A message from our CEO

Publication

Quantitation of free and total N-acetylcysteine amide and its metabolite N-acetylcysteine in human plasma using derivatization and electrospray LC-MS/MS.

Publication

Assessment of the Biotransformation of Low Turnover Drugs in the HμREL Human Hepatocyte Coculture Model.

Publication

Measurement of lidocaine and 2,6-dimethylaniline in minipig plasma, skin, and dermal tapes using UHPLC with electrospray MS/MS.

Publication

11th GCC Closed Forum: cumulative stability; matrix stability; immunogenicity assays; laboratory manuals; biosimilars; chiral methods; hybrid LBA/LCMS assays; fit-for-purpose validation; China Food and Drug Administration bioanalytical method validation

Publication

Complementary techniques for challenging radiolabeled in vivo/in vitro metabolism studies: Advantage and limitation.

Publication

Recommendations for Selection and Characterization of Protein Biomarker Assay Calibrator Material

Publication

Proprotein Convertase Subtilisin Kexin 9 (PCSK9)

Publication

Novel Biomarkers of Diabetic Nephropathy

Publication

Kidney Safety Biomarkers

Posts navigation

Older posts
About Nexelis, a Q² Solutions Company

With unrivaled expertise in immunology, 5 operating sites in North America and Europe, and a translational offer of services covering the needs of the pharmaceutical industry from the lead selection to the late clinical stage, Nexelis, a Q² Solutions Company, is a leading provider of assay development and advanced laboratory testing services in the infectious, metabolic and oncologic fields. Our versatile team of scientists, working with state of the art technology platforms, were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 350 new molecular entities, including blockbuster vaccines and biologics, anti-viral drugs, immunotherapy, gene and cell therapy products.

A Q2 Solutions Company


Contact Us

Q2 Solutions, a wholly owned subsidiary and laboratory division of IQVIA, is a leading global clinical trial laboratory services organization providing comprehensive testing, project management, supply chain, biorepository and specimen management, and clinical trial sample and consent tracking solutions. Learn more at www.q2labsolutions.com.

Contact Us

Careers
Quality Assurance
Information Technology

Follow Us LinkedIn Twitter YouTube

© 2022 Nexelis, a Q² Solutions Company. All Rights Reserved.

  • Legal & Compliance
  • Terms of Use
  • What’s Next
  • Our Services
    • Early Development Assays
    • Preclinical
    • Protein Sciences
    • Bioanalytical Services
      • Menu
    • Biomarkers
      • Menu
    • Translational Sciences
    • Assay Development and Technology Transfer
    • High-Throughput Testing
  • Our Expertise
    • Infectious Diseases
      • Vaccine
      • COVID-19
    • Immunotherapy
      • Immuno-oncology
    • Metabolic Diseases
  • About Us
    • About Us
    • Our Sites
      • Laval
      • Seattle
      • Gosselies
      • Indianapolis
      • Marburg
      • Porton Down
    • Our Scientists
  • News & Events
    • News
    • Events
  • Resources
  • Careers
  • Blog
  • Contact Us
  • English
    • French
    • German